NEWTON, Mass.--(BUSINESS WIRE)--PGxHealth®, a division of Clinical Data, Inc. (NASDAQ: CLDA), today announced its participation in the international mAb IMPACT meeting which is focused on IMProving ACTivation of the FCGR3A pathway for optimizing the treatment of cancer. At this meeting, funded by the French Institut National du Cancer and supported by leading academic and industry organizations including PGxHealth, experts will discuss how genetic variation in the FCGR3A pathway can be employed to improve clinical outcomes in the treatment of lymphomas, breast and colorectal cancers with rituximab, trastuzumab and cetuximab, respectively, and other recombinant monoclonal antibodies (mAbs). This effort complements PGxHealth’s FCGR program, which includes its PGxPredict™:RITUXIMAB, a test for genetic variation in the FCGR3A gene that can be used to determine response to rituximab monotherapy in the treatment of follicular non-Hodgkin’s lymphoma.
